The discovery of the haematopoietic growth factor granulocyte colony-stimulating factor (G-CSF) has reduced infection-related morbidity in cancer patients by alleviating post-chemotherapy neutropenia. Two formulations of recombinant human (rh) G-CSF, one glycosylated and one non-glycosylated, are available. The glycosylated form, lenograstim, possesses at least 25% greater bioactivity in vitro. Some comparative studies into the preparation's potential to mobilise haematopoietic stem cells suggest a similar advantage. In the light of the great clinical importance of G-CSF, we have performed the first prospective, randomised, crossover study on children with chemotherapy-induced neutropenia. G-CSF (250 g/m 2 ) was started 1 day after the chemotherapy block, and was administered until a WBC Ͼ1500/l was achieved on 3 successive days. Thirty-three G-CSF cycles from 11 patients (16 lenograstim, 17 filgrastim) were studied. They were investigated for duration of very severe (WBC Ͻ500/l, 9 vs 9.5 days, lenograstim vs filgrastim, median) and severe leukopenia (WBC Ͻ1000/l, 11 vs 11 days), infections (CRP Ͼ5 mg/dl, 5 vs 5.5 days), infection-related hospital stay (11 vs 9 days) and antibiotic treatment (9 vs 9 days). Statistical evaluation by paired analysis could not detect any difference between treatment groups; the median difference for all end-points was zero. In summary, at least at 250 g/m 
haematopoietic cells committed to the neutrophil lineage (CFU-G).
1,2 It also regulates some functions of the mature neutrophil, including chemotaxis, migration, and superoxide production. 3 These effects are pivotal to the repeatedly demonstrated ability of exogenous G-CSF to reduce length and severity of post-chemotherapy neutropenia. In doing so, it could significantly reduce incidence and severity of neutropenic infection, thus decreasing morbidity and health care expenditure. [4] [5] [6] G-CSF is also being used to mobilize haematopoietic stem cells into the peripheral blood in both healthy volunteers 7, 8 and chemotherapy-treated patients.
9,10
The purification and molecular cloning of G-CSF were performed in the mid-1980s, and the first recombinant human (rh)G-CSF, filgrastim, was approved in the USA for clinical use in chemotherapy-treated cancer patients in 1991. 11 Filgrastim is produced in E. coli. Unlike the natural G-CSF molecule, which is O-glycosylated at the Thr-133 position, 12 it contains no sugar moiety, but is otherwise very similar in its amino acid sequence and steric conformation. The potency of filgrastim has been reported to be precisely the same as that of the natural G-CSF. 13 Most clinical data on G-CSF has been gathered with filgrastim. Lenograstim was licensed in Europe and Japan in 1993. 11 It is produced in Chinese hamster ovary cells, which has permitted the introduction of carbohydrate chains identical to those of the natural G-CSF molecule. 12 Lenograstim is thus more similar to the natural G-CSF, but the clinical relevance of this remains to be determined. While it has been conclusively demonstrated that glycosylation is not vital for the biological activity of rhG-CSF, 14 the carbohydrate moiety does appear to confer greater stability to the G-CSF molecule [15] [16] [17] by protecting the cysteine-17 sulfhydryl group. 18 On the other hand, clearance of the glycosylated G-CSF molecule appears to increase with prolonged application. 19 The effect of glycosylation of the G-CSF molecule on its potency in vivo is thus not predictable. The safety and efficacy of both preparations has been demonstrated independently, [4] [5] [6] 20, 21 but comparative data are scarce.
In vitro studies have suggested a more than 25% greater potency of lenograstim compared to filgrastim. 14, [22] [23] [24] This was believed to be the result of the inferior chemical stability of filgrastim, which resulted in a decreased half-life in culture media. [14] [15] [16] 22 This belief was supported by the experiments of Querol et al 24 who demonstrated that daily repletion of G-CSF in the media could abrogate the difference in potency. Some groups have suggested that lenograstim might also possess greater potency in vivo. Therefore, two comparative animal studies were performed. One study, performed by Nohynek et al 25 at the laboratories of Rhône-Poulenc Rorer, looked at the impact of the two G-CSF preparations on the recovery of cyclophosphamide-treated mice. In both the lenograstim and the filgrastim groups the leucocyte nadir was reached on day 4, a 1 day advantage over the control animals. On day 12, both groups had reached pre-treatment leucocyte counts. Another study investigated pharmacokinetics and maximum leucocyte counts in G-CSF-treated monkeys. 26 With subcutaneous injection, bioavailability, plasma levels and maximum leucocyte counts were identical. These data not only failed to substantiate the proposition that lenograstim might be more potent than filgrastim, but also suggested that the decreased in vitro stability of filgrastim might not be observed in vivo.
Comparative studies in humans have all looked at stem cell mobilisation, but their results were inconclusive. In a group of healthy volunteers, Høglund et al 27 found lenograstim to be 25% superior to filgrastim in terms of CD34 + cell and CFU-GM mobilization. The same study design was used by Watts et al. 28 However, in their study there was no difference in CD34 + cell mobilisation, but the number of GM-CFC was higher in the lenograstim-treated subjects.
Watts et al
28 also compared day-1 G-CSF plasma levels and found filgrastim levels to be significantly higher than lenograstim levels. These data again indicate that the decreased stability, which resulted in the inferior in vitro performance of filgrastim, should not play a role in vivo. However, comparison of plasma levels is not necessarily a good measure of effect, since plasma levels may only inadequately correlate with receptor binding. The authors therefore suggest other mechanisms involving ligandreceptor interaction by which a greater potency of G-CSF might be achieved. A number of studies have looked at stem cell mobilization in chemotherapy-treated patients, but failed to find a difference between the two preparations. 29, 30 Thus, while the in vitro situation is quite clear, there is some reason to doubt a difference in potency of lenograstim and filgrastim in vivo.
Data comparing the two drugs' potential for reducing neutropenia, morbidity from neutropenic infection, hospital days, and antibiotic treatment, is lacking altogether. In a prospective, randomised, crossover study, we have therefore compared blood counts, C-reactive protein values (CRP), and infection-related clinical events in patients receiving growth factor support with lenograstim or filgrastim following cytoreductive chemotherapy.
Materials and methods

Patients
Between August 1997 and August 1999, 11 patients, three female and eight male, aged between 3 and 29 years (median, 14 years) were included in the study. The investigation was performed as a monocentre study at the Heinrich-Heine University Center of Child Health, Department of Paediatric Haematology and Oncology. This prospective study was open for all patients who on clinical judgement were considered at у50% risk of developing severe neutropenia, or were to receive rhG-CSF routinely as part of their chemotherapy protocol. Patient details are given in Table 1 . Written informed consent was obtained from the patients or their guardians. The study was performed in accordance with the current version of the Declaration of Helsinki and had been approved by the local Ethics Committee under the condition that no additional blood draws or outpatient clinic visits should become necessary. Thirty-three cycles of rhG-CSF treatment were evaluated.
Treatment
RhG-CSF was started 1 day after the end of the chemotherapy block. It was administered once daily by subcutaneous injection at a standard paediatric dose of 250 g/m 2 ± 5%. A dose-response relationship for G-CSFsupported abbreviation of chemotherapy-induced neutropenia has been established for doses between 0.5 and 60 g/kg, 31,32 thus 250 g/m 2 (or 6 g/kg) constitutes a medium dose. RhG-CSF was continued until a white blood count (WBC) of Ͼ1500/l had been measured for 3 successive days after the end of the expected leucocyte nadir. Table 1 Age, sex, diagnosis, and chemotherapy of the 11 patients included in this study Thirty-three cycles (22 cross-over pairs) of rhG-CSF therapy were investigated. All doses, unless otherwise specified, are mg/m 2 . Diagnoses: EWS = Ewing's sarcoma; ARH = alveolar rhabdomyosarcoma; OS = osteosarcoma; (r)ERH = (recurrent) embryonal rhabdomyosarcoma; NBL = neuroblastoma; PNET = primitive neuro-ectodermal tumor. Chemotherapeutic agents: VP16 = etopside; Ifo = ifosfamide; VCR = vincristine; ActoD = actomycin D; Carbo/CisPt = carbo/cisplatin; HT = deep regional hyperthermia; Adr = adriamycin; Cyc = cyclophosphamide; Topo = topotecan; AraC = cytarabine.
Study design
The trial was designed as a prospective, randomised, open, crossover monocentre phase-III study. The patients were treated alternatingly with lenograstim (Granocyte; Rhône-Poulenc Rorer, Cologne, Germany) and filgrastim (Neupogen; Amgen, Munich, Germany). The randomisation for which preparation they would receive in the first cycle was made by lot. Two consecutive cycles with the same or very similar chemotherapies, but with different growth factor preparations, were to be investigated for differences by paired analysis.
At every visit at the outpatient clinic, the patients were given a full physical examination, and a blood draw. For the evaluation, the following end-points or events were defined: leukopenia (WBC р1000/l), severe leukopenia (WBC р500/l), neutropenia (absolute neutrophil count (ANC) р1000/l), severe neutropenia (ANC р500/l), presumed infection (CRP Ͼ5 mg/dl), infection-related hospital stay (hospital stay with antibiotic treatment; hospital stay for other reasons was disregarded), antibiotic treatment (treatment with antibiotics other than pneumocystis prophylaxis with co-trimoxazole). Elevated CRP rather than pyrexia was used as indicative of an infection, since a number of effects may influence body temperature, including ambient temperature and pyrexic (amphotericin B) or antipyrexic (metamizole, acetaminophen) effects of certain medications. The duration of rhG-CSF treatment was also monitored. If on some days no differentials were available, the ANC was nonetheless counted as Ͻ500/l or Ͻ1000/l, if the WBC was Ͻ500/l or Ͻ1000/l, respectively. For the evaluation of WBC (ANC) at one of the critical time points (500 or 1000 cells/l), no more than 2 days (3 days) were allowed to lie between two leucocyte counts (differentials), or the cycles would be excluded from the evaluation of WBC (ANC) kinetics.
Methods
Leucocyte counts were performed in the routine laboratory with an automatic cell counter. CRP was determined by standard laser nephelometry. If the WBC was Ͼ500/l, blood smears were prepared and Pappenheim-stained, and differentials were hand-counted by light microscopy.
Statistical analysis
The condition for eligibility for crossover testing was that the same, or very similar chemotherapeutic agents, but different growth factors, had been given in two consecutive cycles. Two immediately consecutive cycles were compared in pairs using the Wilcoxon signed-rank-test for paired analysis. Differences were calculated as (time (days) with lenograstim treatment) − (time (days) with filgrastim treatment); thus negative 'differences' indicate a superiority of lenograstim, positive ones a superiority of filgrastim. In order to detect putative carry-over effects, the groups which had received, respectively, lenograstim or filgrastim first, were compared with the Mann-Whitney U-test for unpaired analysis. If more than one pair of cycles was gained from one patient, these were nonetheless considered independent events. Thus, if a patient received drug A in cycle 1, drug B in cycle 2, and drug A in cycle 3, cycles 1 vs 2, and cycles 2 vs 3 were compared as two independent pairs. A P Ͻ 0.05 was considered significant, no adjustment for multiple testing was made. Confidence intervals and power analysis were calculated with the nQuery software. The study was estimated to be sufficiently powerful to detect as 'statistically significant' difference Ͼ2 days for the parameters duration of WBC Ͻ1000/l, WBC Ͻ500/l, ANC Ͻ1000/l and treatment duration (Ͼ3 days for ANC Ͻ500/l) with a test significance level ␣ = 0.05, and a power of 80%.
Results
Patient characteristics
The 11 patients received a total of 33 cycles of G-CSF treatment (2-5 cycles, median three cycles per patient), 16 with lenograstim, 17 with filgrastim. This yielded 22 crossover pairs, of which 12 received lenograstim in the first, and filgrastim in the subsequent cycle, and 10 received filgrastim first, and lenograstim thereafter. In order to detect putative carry-over effects, the 'lenograstim first' and the 'filgrastim first' groups were compared with the MannWhitney U-test for unpaired analysis. No differences could be detected for any of the end-points. Thus, there appeared to be no carry-over effects, so that the order in which the growth factors were given did not have to be taken into account in the subsequent analyses. G-CSF was tolerated well; no major adverse effects were reported that were attributable to G-CSF treatment. For the paired analysis, in three patients minor differences between the chemotherapies were accepted. Thus, in one patient, the first of three cycles with ifosfamide, etoposide and vincristine was supplemented with actinomycin D, one patient was alternated between adriamycin and actinomycin D in addition to ifosfamide, etoposide, and vincristine, and in the third patient, the third and fourth cycles of high-dose cyclophosphamide and etoposide were supplemented with a radiation boost to the tumor bed ( Table 1) .
Duration of leukopenia/neutropenia
Sixty-nine percent (11/16) of the lenograstim, and 76% (13/17) of the filgrastim-treated patients dropped to a WBC Ͻ1000/l, and in both groups on day 9 of growth factor treatment, у50% of the patients (10/16 vs 10/17) had recovered a WBC of у1000/l. Only 42%/41% (7/16 vs 7/17) of each of the treatment groups ever had a leucocyte nadir of Ͻ500/l. In all patients, the ANC dropped to below 1000/l (n = 30 cycles); in both groups, day 11 was the first day on which у50% of the patients (7/13 vs 10/17) had returned to an ANC у1000/l. Very severe neutropenia (ANC Ͻ500 l; n = 29) was observed in 77% (10/13) vs 69% (11/16) of patients in each of the treatment groups, and on day 9, у50% of patients had recovered their ANC to у500/l in both groups (7/13 vs 8/16) (Figure 1 ). According to the power analysis, a difference between lenograstim and filgrastim for WBC Ͻ1000/l and ANC , ANC Ͻ1000/l (c), and ANC Ͻ500/l (d). 44% of the lenograstim-treated and 41% of the filgrastim-treated patients had a WBC nadir Ͻ500/l, 67 vs 76% had a WBC nadir Ͻ1000/l, 77 vs 69% an ANC nadir Ͻ500/l. All patients dropped to an ANC Ͻ1000/l. In both groups, 50% achieved a WBC у1000/l, ANC у1000/l, or ANC Ͼ500/l on days 9, 9, and 11, respectively. Ͻ1000/l of Ͼ2 days, equivalent to Ͼ28% and Ͼ18%, respectively, would have been detected. Comparison of pair differences yielded 0 (−2.3-1.3) days (median (95% confidence limits of the mean)) for the end-point WBC Ͼ500/l, 0 (−3.3-0.9) days for WBC Ͼ1000/l, 0 (−2.0-4.5) days for ANC Ͼ500/l and 0 (−0.9-2.7) days for ANC Ͼ1000/l. Box plots are displayed in Figure 2 . Thus incidence, severity, and duration of leuko-and neutropenia followed the same pattern in lenograstim-or filgrastim treated-patients.
Length of rhG-CSF treatment
The duration of growth factor therapy was the same for both groups. Lenograstim was administered for 12.5 (7-18) days (median (range)), filgrastim for 12 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) days. Power analysis revealed that a difference Ͼ2 days for treatment duration would have been detected. This would have been equivalent to a difference of Ͼ16% (test significance level ␣ = 0.05, power 80%). The difference among the pairs was 0 (−4-7) days (Figure 2) . No difference was detectable between lenograstim-or filgrastim-treated patients.
Infection
Events defined as related to infection were observed in a minority of patients, but were equally common in both treatment groups. Thus, infections (CRP Ͼ5 mg/dl) were observed in 33% (5/15) vs 35% (6/17) of patients, they lasted 5 (4-9) (median (range)) vs 5.5 (3-12) days in lenograstim-vs filgrastim-treated patients. Median difference in the length of infectious episodes was 0 days, with a range of −8-7 days. The 95% confidence limits of the mean were −1.8-0.9. 58% (7/12) vs 60% (9/15) of patients received antibiotic treatment for an average of 9 (1-12) vs 9 (2-17) days (median (range)). The median difference was 0 days, with a range of −2-6 days. 25% (3/12) vs 50% (7/14) of patients were re-admitted or retained in hospital because of infections; the average infection-related hospital stay lasted 11 (6-12) vs 9 (3-14) days (Figure 2 ). Median (range) of the pair differences for infection-related hospital stay was 0 (−5-6) days, the confidence limits of the mean were −2.1-1.2. None of these differences were statistically significant.
Discussion
For the in vitro system, a greater potency of lenograstim has repeatedly been demonstrated. 14, 17, [22] [23] [24] This was, at least in part, explained by the greater pH resistance of the glycosylated molecule, since repletion of G-CSF could abolish the difference. 17, 24 A number of clinical studies have compared the two drugs' potency for stem cell mobilisation, and they have come to conflicting results. Thus in chemotherapy-treated, neutropenic hosts Schiødt et al 29 and Saccardi et al 30 found no difference in potency between the two preparations. However, these were non-randomised studies, and no power analysis was performed, so that it remains elusive how big the difference would have needed to be in order to be detected. In randomised cross-over studies with healthy individuals, lenograstim was reported to be more potent as a mobiliser of CD34 + cells 27 and/or of GM-CFC. 27, 28 For all four studies, it must be said that the very subtle kinetics of G-CSF-induced stem cell mobilisation 33 are probably not sufficiently reflected by once daily determination of CD34 + count or progenitor cell culture. The data available at present are thus not sufficient to justify any general statement about differences in potency of the two G-CSF preparations.
An important negative feedback regulator of G-CSF is its neutralisation by mature neutrophils. 34 This implies, that the pharmacokinetics of rhG-CSF will be quite different in neutropenic and non-neutropenic individuals. 19, 35 However, while the effect of the presence of neutrophils increases daily, the pharmacokinetic studies were only done on day 1 of G-CSF treatment. 28 If glycosylated rhG-CSF was neutralised less effectively by neutrophils, this could explain better CD34 + or GM-CFC harvest and higher maximum WBC in probationers with very high neutrophil counts. 25, 27, 28 During neutropenia, this difference would not come into play, which might explain why, even if there were a difference between the two G-CSF preparations in terms of receptor binding, in neutroBone Marrow Transplantation penic hosts consistently no difference was found between glycosylated and non-glycosylated G-CSF. 29, 30 As was mentioned above, the greater physical stability of the glycosylated molecule 17 appears to confer to lenograstim an advantage in the in vitro system. In vivo, however, this appears not to be the case. Bioavailability with subcutaneous injection and plasma levels were identical in humans 28 and monkeys. 26 A number of factors may contribute to this. The stable physical environment and the continuous release from a subcutaneous depot may reduce the contribution of filgrastim's lesser physicochemical stability. In vivo, clearance will much rather be the result of loss through proteolysis and neutralisation due to receptor binding and integration. The available studies suggest that these clearance mechanisms affect the two preparations similarly. Renal clearance of G-CSF has also got to be considered, since some of the cancer patients might have sustained relevant renal damage which would increase plasma levels. 36 Differential effects of renal dysfunction on glycosylated and non-glycosylated G-CSF are conceivable, but were never studied. This is the first study looking at differential effects of the two preparations on the kinetics of chemotherapy-induced neutropenia in humans. We could here demonstrate that at a standard paediatric dose of 250 g/m 2 , lenograstim and filgrastim did not differ in their effect on duration and severity of neutropenia, and on the frequency and clinical course of infections. The power of the study would have been sufficient to detect a difference in the range of that postulated by Høglund et al, 27 ie a 25% advantage for lenograstim.
Our data suggest that the in vitro dose equivalence of different rhG-CSF preparations may not be applicable in vivo, at least not in neutropenic patients. Rather, in children at 250 g/m 2 , lenograstim and filgrastim are identical in their effects on neutrophil engraftment and the development of infectious complications. Differences in the biologic effects at other doses can not be ruled out. In children and adolescents, and at a dose of 250 g/m 2 , the two drugs can probably be used interchangeably. This would permit the selection of the rhG-CSF preparation on the basis of vial size in relation to the patient's body surface area, of cost, and of individual tolerability.
